<DOC>
	<DOCNO>NCT00520767</DOCNO>
	<brief_summary>RATIONALE : Giving bortezomib together melphalan dexamethasone may effective treatment primary amyloidosis light chain deposition disease . PURPOSE : This phase II trial study well give bortezomib together melphalan dexamethasone work treat patient primary amyloidosis light chain deposition disease .</brief_summary>
	<brief_title>Bortezomib , Melphalan , Dexamethasone Treating Patients With Primary Amyloidosis Light Chain Deposition Disease</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine complete hematologic response rate 12 month . Secondary - Determine overall hematologic response rate . - Determine organ response rate . - Determine time treatment failure . - Assess toxicity regimen , term incidence severity treatment-emergent peripheral neuropathy quality life . - Determine overall survival . OUTLINE : This multicenter study . Patients receive oral melphalan day 1-4 , bortezomib IV day 1 , 8 , 15 , 22 , dexamethasone orally IV day 1 , 2 , 8 , 9 , 15 , 16 , 22 , 23 . Treatment repeat every 4-6 week 20 course absence disease progression unacceptable toxicity . Blood , urine , bone marrow aspirate collect baseline periodically treatment permit correlation clinical result measure molecular event . A single baseline peripheral blood DNA sample collect future association study link disease onset , progression , response administer therapy single nucleotide polymorphism . Blood plasma urine sample evaluate proteomic marker associate disease progression therapeutic response . Peripheral blood RNA sample evaluate transcriptional response treatment peripheral blood lymphocyte . Bone marrow aspirate collect extract plasma cell flow cytometry gene expression profile . Quality life assess begin course .</detailed_description>
	<mesh_term>Amyloidosis</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Biopsyproven diagnosis 1 following : Primary systemic amyloidosis Histochemical diagnosis amyloidosis determine polarize microscopy green birefringent material Congo redstained tissue specimen characteristic electron microscopy appearance Light chain deposition disease Measurable disease define one following : Serum monoclonal protein ≥ 0.5 g/dL serum electrophoresis Urine monoclonal protein &gt; 200 mg/tv 24 hr urine electrophoresis Serum immunoglobulin freelight chain ≥ 10 mg/dL AND abnormal serum immunoglobulin kappa lambda free light chain ratio Must meet 1 follow criterion : Clonal population plasma cell bone marrow ( ≤ 30 % ) Immunohistochemical stain antilight chain antiserum amyloid fibril Must meet follow diagnostic criterion symptomatic* multiple myeloma : Lytic lesion skeletal survey Plasmacytoma Increase bone marrow plasma cell ≥ 30 % NOTE : *Patients meet International Myeloma Working Group definition symptomatic multiple myeloma symptom attributable associate amyloidosis otherwise meet criterion diagnosis smolder myeloma potentially eligible upon approval principal investigator . If previously treat , patient either candidate autologous stem cell transplantation ( ASCT ) decline option ASCT Patients undergone prior ASCT subsequently progress eligible , provide eligibility criterion meet No secondary familial amyloidosis PATIENT CHARACTERISTICS : ECOG performance status 03 Creatinine &lt; 5 mg/dL Bilirubin &lt; 2.5 time upper limit normal ( ULN ) ALT AST &lt; 3 time ULN Absolute neutrophil count ≥ 1,000/mm³ Platelet count ≥ 80,000/mm³ Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Peripheral sensory neuropathy &lt; grade 3 No myocardial infarction within past 6 month No New York Heart Association class III IV heart failure No uncontrolled angina No severe uncontrolled ventricular arrhythmia No EKG* evidence acute ischemia active conduction system abnormality ( include 1st degree AVblock , Wenckebach type 2nd degree heart block , leave bundle branch block ) NOTE : *Prior study entry , EKG screen abnormality must document investigator medically relevant ; low limit LVEF patient exclude participation No hypersensitivity bortezomib , boron , agent utilize study No serious concurrent illness ( e.g. , stroke ) within past 30 day No psychiatric illness likely interfere study participation No untreated HIV infection Patients asymptomatic HIV infection active antiretroviral therapy potentially eligible No diagnosis treatment another malignancy within past 3 year , except completely resect basal cell squamous cell carcinoma skin , situ malignancy , lowrisk prostate cancer curative therapy PRIOR CONCURRENT THERAPY : See Disease Characteristics No investigational drug within past 14 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>primary systemic amyloidosis</keyword>
	<keyword>light chain deposition disease</keyword>
</DOC>